

INOVIO BIOMEDICAL CORP
Form 8-K
December 06, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 30, 2005

Inovio Biomedical Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-14888

33-0969592

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

11494 Sorrento Valley Road, San Diego,
California

92121-1318

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(858) 597-6006

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 1.01 Entry into a Material Definitive Agreement.

On November 30, 2005, the registrant, as payee, and Verdas Invest Ltd. ("Verdas"), and Baystar Capital II, L.P. ("Baystar"), each as payors, agreed to extend by fifteen days the due date for payment of that certain promissory note dated January 10, 2005 in the principal amount of \$2,430,000 payable to registrant by Verdas and Baystar, respectively (the "Note"). The previous due date under the Note was November 30, 2005 and, as extended, is now December 15, 2005. The Note was one of three of promissory notes delivered to the registrant by Verdas, Baystar and another "Purchaser" on January 10, 2005 in a transaction (the "Transaction") reported by the registrant in its Form 8-K dated and filed with the SEC on January 13, 2005.

As originally reported, the Note from Baystar received by the registrant in the Transaction (including the Note extended as discussed in this Report) is payable, at the election of Baystar, either in cash or with shares of the registrant's Series C Cumulative Convertible Preferred Stock valued at the liquidation preference (as defined in the Certificate of Designations, Rights and Preference of Series C Cumulative Convertible Preferred Stock of the registrant). Except for extending the due date of the Notes, no other changes in the payment or other terms of the Notes was made.

Except for the relationship created by the Transaction, there is no material relationship between the registrant or its affiliates and Verdas or Baystar.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Letter agreement dated November 30, 2005 between registrant and Verdas extending due date of the Note.

99.2 Letter agreement dated November 30, 2005 between registrant and Baystar extending due date of the Note.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Inovio Biomedical Corporation

December 6, 2005

By: /s/ Peter Kies

Name: Peter Kies

Title: Chief Financial Officer

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Letter agreement dated November 30, 2005 between registrant and Verdas extending due date of the Note.
99.2	Letter agreement dated November 30, 2005 between registrant and Baystar extending due date of the Note.